Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an Unmet Need in GIST

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

Related Keywords

United Kingdom ,Houston ,Texas ,United States ,London ,City Of ,American ,Neeta Somaiah ,Robin Jones ,Department Of Sarcoma Medical Oncology ,American Society Of Clinical Oncology Annual Meeting ,University Of Texas Md Anderson Cancer Center ,Division Of Cancer Medicine ,Sarcoma Medical Oncology ,Cancer Medicine ,Cancer Center ,Sarcoma Unit ,Royal Marsden ,Data Sets ,Peak Part ,Clinical Oncology Annual Meeting ,Gastrointestinal Stromal Tumor ,Gist ,Imatinib ,